Organic Active Ingredients TRIZ Cases

A water-soluble host-guest complex prevents π-π stacking and quenches triplet states, protecting photosensitizers before controlled ROS generation.

PLGA microspheres adjust polymer composition to deliver progestogen linearly for 6–14 days without an initial burst or lag phase.

Seed crystals guide amlodipine mesylate monohydrate growth, limiting explosive crystallization and improving flow for direct tablet pressing.

Surgical removal and radiation leave prevention gaps; this polymorphic sodium salt is used before osteoblast-driven bone formation develops.

Blood-based FAM19A5 detection supports pre-symptomatic CNS disease diagnosis by measuring protein levels before clinical symptoms appear.

Genomic screening selects disulfiram, elesclomol, or thiram for cancers with 16q loss or low metallothionein expression.

Electrospraying converts therapeutic or diagnostic liquids into low-aggregation particles that support concentrated, low-volume dosing through standard injectors.

MFGM-rich whey protein, α-lactalbumin, phospholipids, and oligosaccharides support probiotic colonization and intestinal barrier function.

GMP-compliant lipid mixing and defined charge ratios help preserve RNA activity and product quality during extended storage.

Controlled psilocybin dosing and psychological support address limited options across anxiety, headache, and eating disorders.

Selective compounds target NLRP3 inflammasome activity to address inflammaging while limiting off-target effects and immune suppression.

Buffer and glycol or polyol cosolvents help stabilize lisdexamfetamine oral solutions against alkaline and oxidative degradation.

Composite lipid and inorganic nanoparticles protect RNA from degradation while enabling cellular delivery and in-body imaging.

Systematic substituent changes create PARG-inhibiting compounds that can increase cancer-cell sensitivity to DNA-damaging agents.

Controlled crystallization forms a five-and-a-half hydrate of treprostinil sodium salt with improved stability and reduced moisture absorption.

Formula (I) amide compounds inhibit CSF-1R to address cancer, autoimmune, and inflammatory diseases across diverse treatment contexts.

Large genetic constructs challenge viral vectors; RAFT polymer nanoparticles support tissue-directed non-viral delivery with immune evasion.

Aged tissues suppress angiogenesis as endothelial cells enlarge; ML141 stimulates YAP1 nuclear translocation to reduce cell size and restore vessel growth.

See how tetrafluorobenzyl compounds used with thrombolysis or thrombectomy target reperfusion injury and hemorrhagic transformation.

Step-up epcoritamab dosing gradually recruits T cells to CD3/CD20-positive cancer cells while limiting cytokine storm in B-NHL.

Short-lived CD73 inhibitors can require frequent dosing; optimized pharmacokinetics support parenteral intervals of up to four weeks.

Two stable solabegron zwitterion crystal forms address laboratory-scale production limits and support pharmaceutical manufacturing.

Degron-linker compounds target PTPN2 and PTPN1 for proteasomal degradation, enhancing IFNγ signaling and tumor response.

EDTANa4 binds metal ions in LABA pMDI formulations, helping limit degradation and maintain active-ingredient stability over time.

Anti-CD24 antibodies, RNAi agents, and small molecules reduce hepatic steatosis in fatty liver and obesity-related disease.

By preserving plasmin activity, chymase inhibitors accelerate fibrin clot lysis and vessel re-opening while minimizing bleeding complications.

During CPR, PEG-20k creates osmotic gradients that limit cell swelling and support coronary perfusion and organ recovery.

Replacing cyclodextrin with co-solvents, surfactants, and nanocrystal inducers supports stable posaconazole IV delivery without central venous access.

Reconstitution can hinder cyclophosphamide administration; this ready-to-use liquid approach uses solvents and antioxidants to improve storage stability.

To address inconsistent outcomes and difficult T-cell identification, the case expands neoantigen-reactive clones and selects immunogenic TCRs.

See how orally administered small RNAs target PCSK9 to lower LDL-C while addressing statin-related myalgia and hepatotoxicity.

Fluoromethyl compounds activate CaV1.2 to increase calcium current amplitude while minimizing cardiovascular side effects.

Cyclodextrin removes excess lipids while VEGF-overexpressed stem cells support neuroprotection and angiogenesis in neurodegenerative disease models.

Selected 5′ and 3′ UTR elements boost transient Cas9 or Cpf1 expression for efficient genome editing with fewer off-target effects.

Non-depletional B cell inhibition helps reduce anti-drug antibodies and rejection reactions during Barth syndrome gene therapy.

Combining HTLV-1 Gag and Env nucleic acids forms secreted virus-like particles that elicit immunity against infection.

Castor oil can make fulvestrant injections painful and require refrigeration; alternative excipients target lower irritation and 24-month stability.

Oral collagen is degraded and topical collagen cannot penetrate skin, so pyrimidine nucleotides stimulate fibroblasts through epidermal cells.

Combining anti-GD2 therapy with tipifarnib inhibits tumor-derived sEV secretion and helps restore immune activity against resistant neuroblastoma.

A multivalent DR5 agonist paired with an IAP antagonist activates complementary apoptotic pathways to overcome cancer-cell resistance.

Pyrimidine compounds use structural substitutions to treat diverse seizures while limiting motor dysfunction from disrupted neuronal balance.

A granulation and external-lubrication process forms cores with at least 70 wt% drug while supporting low friability, rapid disintegration, and smooth tablet ejection.

Glycosylation tunes hydroxytryptamine analogues for serotonin receptor modulation, addressing limited efficacy and side effects.

Replacing hydrogen with deuterium at the stereogenic center helps prevent racemization in quinazolinone piperidine diones.

Learn how a non-aqueous naloxone vehicle supports localized skin delivery while limiting naloxone N-oxide during storage.

Polar aprotic solvents such as DMA and DMSO help keep lipophilic protides soluble and stable for intravenous delivery at therapeutic doses.

Focused ultrasound transiently opens the blood-brain barrier, enabling time-point sampling to improve brain biomarker sensitivity and accuracy.

Substituent changes tune Kv3 modulators toward in vivo potency, channel selectivity, safety, and brain availability.

Conditional capacitor selection and shared-inductor switching reduce cross-regulation and dynamic power dissipation across varying loads.

Existing treatments lack effective IKKα inhibition; these compounds target the kinase to address cancer progression pathways.

Selective Nurr1:RXRα activation halts neuronal degeneration and regulates dopamine production without inducing dyskinesias associated with L-DOPA therapy.

Alpha-aminoamide derivatives target multiple neurotransmitter systems to improve cognitive symptoms while reducing side effects from dopaminergic antagonism.

A two-phase system uses lecithins and glycerol to form stable micelles without synthetic surfactants.

Merging HVJ-E immunostimulation with anti-PD-1 blockade overcomes limited monotherapy efficacy to enhance cancer cell proliferation suppression.

Controlled drospirenone formulations reduce peak plasma concentrations to improve patient tolerance while maintaining reliable contraceptive efficacy.

Removing L-menthol prevents ester degradation and skin irritation while maintaining adhesion durability.

Selective small molecule inhibitors target the nucleotide binding site of Rab7 GTPase, resolving adverse side effects from non-specific prenylation strategies.

Encapsulating berberine in heparin-chitosan nanoparticles overcomes low absorption rates, sustaining anti-IgE effects for 20 weeks.

Granulation separates gas generating agents from acid components to maintain chemical purity in effervescent formulations.

A porous polymeric matrix reversibly immobilizes an isoalloxazine-based catalyst to enhance structural stability and catalytic efficiency.

Specific PDE 7 modulators address the trade-off between therapeutic effectiveness and compound selectivity using local quality design.

Detecting UBQLN2 gene mutations enables precise identification of genetic causes in amyotrophic lateral sclerosis patients.

G-quadruplex forming modified oligonucleotides bind nucleolin on cancer cells to trigger apoptosis while minimizing toxicity to normal tissue.

Polymeric particles with urea-based peptidase inhibitors bind prostate-specific membrane antigen to deliver therapeutic agents.

Novel bicyclic diamine compounds inhibit Janus kinase activity for treating inflammatory and autoimmune disorders.

Pyrimidine-2,4-diamine derivatives inhibit EGFR and HER2 mutations to address rapid resistance development in cancer therapy.

Glycoside treprostinil derivatives reduce subcutaneous injection pain and sepsis risk while maintaining therapeutic efficacy.

KMO inhibitors reduce neuronal damage by blocking toxic metabolite formation while preserving beneficial kynurenine acid production.

Blocking CD96 binding overcomes immune suppression to enhance anti-tumor responses.

Measuring BIN1 isoform ratios enables accurate cancer diagnosis, progression tracking, and treatment efficacy assessment.

Tricyclic sulfone compounds target RORγt to reduce IL-17 levels, addressing insufficient efficacy of current autoimmune therapies.

Pyrazo-tetrahydroisoquinoline derivatives act as dopamine D1 receptor positive allosteric modulators to enhance endogenous signaling pathways.

Charged polymeric dendrimer conjugates deliver nucleic acids to myeloid cells via electrostatic interaction.

Specific particle size ranges in the crystalline PTSA salt of TGR-1202 resolve poor oral bioavailability and pharmacokinetic limitations.

Chemical Formula 1 compound promotes reelin and VEGF-C production, activating lymphatic function to reduce swelling, edema, and obesity.

Tricyclic dibenzothiazepine compounds reverse CDKL5 silencing effects on GluR2 expression and phosphorylation, addressing motor deficits in CDKL5 disorder.

A bismuth-melanin composite absorbs x-rays and gamma rays through photoelectric absorption and Compton scattering mechanisms.

Spirocyclic compounds resolve the contradiction between inhibitor efficacy and selectivity by blocking necroptosis for treating inflammatory diseases.

High-dose biotin halts disease progression in ALS by enhancing brain energy production, addressing safety concerns through intermittent dosing.

Formula I compounds acylate nucleophiles with Lewis acids to produce stereomerically pure amino acid esters, replacing hard-to-access reagents.

Formula I compound reduces viral reservoir size to address drug resistance and treatment complexity in HIV therapy.

Nanoparticulate genistein reduces pulmonary fibrosis by inhibiting NF-kB and pro-inflammatory cytokines during coronavirus infection.

Amphoteric surface modification creates a water film on PLGA microparticles, preventing mucin adsorption and enabling high-efficiency alveolar delivery.

Lipid conjugate prodrug forms a drug reservoir to sustain Entecavir release, resolving frequent dosing and food absorption trade-offs.

A piperazine derivative acts as an MC4 receptor agonist to relax the urethra and reduce residual urine volume.

Non-ionic surfactants improve bendamustine dissolution to resolve IV instability and poor oral bioavailability.

Formula I tricyclic compound targets adenosine receptors to resolve single-target limitations in treating cancer and Parkinson's disease.

Combining triiodothyronine with anti-thyroid agents induces a hypothyroid state to sensitize cancer cells.

Indazole compounds antagonize Wnt pathway activity, addressing limited therapeutic options for aberrant growth states.

7beta-alkyl orvinol analogs modulate peripheral opioid receptors to relieve pain while avoiding central sedation.

A pharmaceutical composition combining uridine monophosphate with butyrate-producing fibers to improve intestinal transit time.

Multi-arm polyethylene glycol derivatives with multiple terminal azido or alkynyl groups enable high-density click chemistry reactions.

Ischemic stimulation in 3D cultures enriches microRNAs to enhance neurogenesis while avoiding whole-cell tumor risks.

Colloidal silicon dioxide coats clopidogrel bisulfate particles to prevent sticking on metal punches and dies during compression.

Segmented yeast particles manage release timing via parameter changes, resolving the trade-off between storage stability and sustained bioavailability.

N3-kethoxal derivatives react selectively with guanine bases to enable precise nucleic acid labeling via click chemistry.

Injectable insulin formulation dissociates hexamers into monomers using EDTA and citric acid for rapid subcutaneous uptake.

Cannabidiol disrupts bacterial membranes and downregulates resistance genes to restore antibiotic effectiveness.

Hybrid macrocycles merge peptoid stability with peptide binding strength to overcome resistance in prostate cancer therapies.

Multi-layered gastroretentive formulations maintain gastric residence and enable sustained drug release.

Molecularly imprinted polymers bind glycan targets through cooperative functional monomers to enable cell imaging and targeted drug delivery.

Topical fusidic acid composition treats non-healing wounds by altering the skin microbiome, reducing scar formation and infection risk.

A 64Zn-enriched zinc composition enhances insulin production and metabolic support in type I diabetes patients.

Segmenting the dosage form into a dissolution-resistant barrier and a diffusion core resolves abuse potential while maintaining extended release duration.

Segmenting polyamine-dihydroxybenzoic acid conjugate hydrogels in the gastrointestinal tract removes excess iron without systemic toxicity.

Ultrasonic decarboxylation stabilizes cannabis-infused vaping liquid, preventing cartridge clogging and reducing waste.

Modified wing regions in a gapmer antisense oligonucleotide enhance RNase H recruitment to degrade RPS25 mRNA and reduce dipeptide repeat production.

GAG mimetics bind to specific sites on IL-13, blocking receptor interaction and resolving the difficulty of identifying conformationally active pockets.

Annealing lipid nanoparticles near the freezing point of water before secondary drying removes moisture while preserving nucleic acid integrity.

Anionic long-chain lipid modifies stratum corneum fluidity, enabling transdermal delivery of hydrophilic molecules larger than 800 Da.

1-Phenylalkanecarboxylic acid derivatives modulate gamma-secretase activity to reduce amyloid-beta 42 production.

Humanized anti-TNF antibodies reduce immunogenicity in juvenile idiopathic arthritis patients while maintaining therapeutic efficacy.

Pulmonary delivery of dimethyl fumarate reverses established lung fibrosis by restoring Nrf2 expression and reducing oxidative stress.

Silencing the AASS enzyme prevents toxic metabolite accumulation in the saccharopine pathway, eliminating dietary restriction burdens.

Modified oligonucleotides inhibit miR-21 activity, regulating fibroblast survival to address inadequate therapeutic options for fibrosis-related diseases.

Ambrisentan selectively blocks endothelin receptor subtype A to prevent renal vasoconstriction, resolving the trade-off between efficacy and fluid retention.

Leptin compositions reduce amyloid beta production and tau phosphorylation to treat progressive cognitive disorders.

Flat plate ascorbic acid crystals in glycerin improve skin spreadability while preventing oxidation instability at high concentrations.

Tianeptine compounds mediate opioid receptor binding to maintain pain relief while activating brainstem pathways that reverse respiratory depression.

Benzocaine in feed masks unpleasant taste to resolve weaning stress and boost intake.

Topical olopatadine compositions inhibit histamine pathways to deliver localized relief from itchy skin.

Modified cardiac glycosides reduce PrPC via endolysosomal degradation, overcoming toxicity and poor brain penetration of existing treatments.

Formula I pyrrolo[3,2-c]pyridin-4-one derivatives inhibit EGFR and HER2 kinases to overcome resistance from exon 20 insertions.

Novel di-substituted 5-membered heteroaryl compounds containing a hydroxamate moiety act as sensitizers to enhance anticancer drug cytotoxicity.

Characterizing brigatinib polymorphs via XRPD ensures consistent drug quality while resolving manufacturing complexity trade-offs.

Deep sequencing quantifies canonical and variant ncRNA ratios, resolving conflicting data to improve prostate cancer diagnosis accuracy.

A human myostatin splice variant protein retains the prodomain to inhibit signaling pathways in muscle tissue.

Heating hops at 60°C to 100°C creates an oxidized composition that enhances memory and attention while reducing bitter taste.

Analyzing BAI3 gene variants predicts QT prolongation predisposition, reducing cardiac risks from drug-induced interval changes.

Cromolyn metal complexes coordinate with bioactive ions to form crystalline structures, improving oral absorption and bioavailability.

Drilling across the fracture line enables uniform biological agent distribution, resolving incomplete union risks in scaphoid fractures.

Masking particles suppress oral taste using a water-insoluble polymer coating, then trigger rapid gastric release via acid-carbonate foaming.

Enteric coating protects the stomach from irritation while micronized particles ensure rapid dissolution for enhanced therapeutic efficacy.

Electrospun polymer fiber scaffolds degrade to release acidic byproducts that alter wound pH and promote tissue regeneration.

Terphenyl compounds inhibit profibrotic signaling to reduce fibrosis levels, addressing ineffective idiopathic pulmonary fibrosis treatments.

Very low dose cyclobenzaprine alleviates fatigue while minimizing side effects, using CAPA2+A3 normalization to objectively monitor treatment effectiveness.

Formula I heteroaryl compounds selectively inhibit RIP1 kinase to treat inflammatory and immune-regulatory disorders.

A recombinant fusion protein combines a TGFβR2 fragment with an anti-PD-1 antibody to capture TGFβ and block PD-L1 interactions.

A traditional Chinese medicine eye drop formulation combines nine herbal extracts to clear heat and detoxify ocular tissues.

A heterocyclic compound antagonizes calcium-sensing receptors to treat heart failure and pulmonary hypertension.